Oleg Nodelman

Extracted Attributes

• Role

  Founder and Portfolio Manager of EcoR1 Capital LLC

• Education

  Bachelor of Science in International Affairs, Georgetown University

• Birthplace

  Kiev, Ukraine

• Biotech Investing Experience

  Over 20 years

Timeline

• Met his future wife, Heather, at the Summer Olympic Games in Atlanta, where he translated Russian and she translated Japanese. (Source: The 2015 Hedge Fund Rising Stars: Oleg Nodelman | Institutional Investor)

  1996-07-19

• Graduated from Georgetown University and moved to San Francisco to work as a consultant at Mercer Management Consulting. (Source: The 2015 Hedge Fund Rising Stars: Oleg Nodelman | Institutional Investor)

  1999-06-01

• Joined BVF Partners as a research analyst, eventually working his way up to portfolio manager over 11 years. (Source: The 2015 Hedge Fund Rising Stars: Oleg Nodelman | Institutional Investor)

  2001-06-01

• Proposed by the Addex Therapeutics Board of Directors for election to its Board. (Source: Addex therapeutics :: Addex Board Proposes Hoyoung Huh and Oleg Nodelman for Election to the Board of Directors)

  2011-03-09

• Founded EcoR1 Capital LLC, a biotech-focused investment advisory firm. (Source: EcoR1 website)

  2013-01-01

• Named one of the Hedge Fund Rising Stars by Institutional Investor. (Source: The 2015 Hedge Fund Rising Stars: Oleg Nodelman | Institutional Investor)

  2015-06-15

• Appointed as Non-Executive Non-Independent Director to the Board of Directors of Galapagos NV. (Source: Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth - BioSpace)

  2024-10-07

Daniel Lurie

Daniel Lawrence Lurie (born February 4, 1977) is an American politician and philanthropist who is the 46th and incumbent mayor of San Francisco, serving since 2025. He was elected in 2024, defeating then-incumbent London Breed. He is the founder and former CEO of Tipping Point Community.

Web Search Results

• EcoR1 website

  Oleg Nodelman is the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech-focused investment advisory firm established in 2013, which invests in companies at all stages of research and development. With over twenty years of experience in biotech investing, Mr. Nodelman has expertise in all aspects of investment management and deep roots in the biotech and scientific communities. Before founding EcoR1, Mr. Nodelman was a portfolio manager at BVF Partners, one of the first hedge funds dedicated to investing in the biotechnology sector. He currently serves as a Board Member for three publicly traded companies: AnaptysBio (NASDAQ: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics applicable to inflammatory and autoimmune diseases;

• Addex therapeutics :: Addex Board Proposes Hoyoung Huh and Oleg Nodelman for Election to the Board of Directors

  Oleg Nodelman, 34, U.S. citizen, is a Portfolio Manager at the Biotechnology Value Fund, a biotech focused investment fund founded in San Francisco in 1993. Before joining BVF, Mr. Nodelman was a consultant with Mercer Management Consulting where he worked closely with senior management on financial and strategic matters. Mr. Nodelman holds a Bachelor of Science in International Affairs and a minor in Science in Technology from the School of Foreign Service at Georgetown University. BVF is a 15.15% shareholder of Addex and on 14 March following conversion of outstanding notes will hold 30% of Addex. [...] # Addex Addex ## Allosteric modulators for human health # Addex Board Proposes Hoyoung Huh and Oleg Nodelman for Election to the Board of Directors Addex Board Proposes Hoyoung Huh and Oleg Nodelman for Election to the Board of Directors Geneva, Switzerland, 9 March 2011 – Allosteric modulation company Addex Pharmaceuticals (SIX:ADXN) announced today that the Board of Directors proposes to the Annual General Meeting of 28 April 2011 that Dr. Hoyoung Huh and Mr. Oleg Nodelman be elected to the Board of Directors of Addex Pharmaceuticals Ltd. [...] Hoyoung Huh, 41, U.S. citizen, is Chairman of the Boards of BiPar Sciences Inc., Geron Corp. (NASDAQ: GERN) and Epizyme Inc. He is a global leader in the biotechnology and healthcare arena, being involved in formation and growth of innovative organizations across the U.S., Europe and Asia. Dr. Huh was BiPar's President and CEO, where he led the merger of BiPar with the French pharmaceutical firm Sanofi-Aventis (EURONEXT: SAN and NYSE: SNY) in 2009. BiPar is now an independent, wholly owned subsidiary and center of innovation within the Sanofi-Aventis Group. He also serves on the Board of Directors at BayBio, Jennerex Inc., SciDose LLC, and on the Presidential Advisory Council of the Berklee College of Music. He was previously a member of the Board of Directors, Chief Operating Officer,

• Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth - BioSpace

  Mr. Nodelman is the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech-focused investment advisory firm which invests in companies at all stages of research and development. Mr. Nodelman brings a wealth of experience in driving shareholder value, strategic transformations, and long-term growth initiatives. With a proven record in investment management – including business development and capital deployment – and his deep roots in the biotech and scientific communities, Mr. Nodelman’s appointment signals Galapagos’ commitment to accelerating value for all shareholders. [...] BioSpace logo # Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Directors, effective October 7, 2024. Mr. Nodelman replaces Mr. Dan G. Baker who stepped down on October 6, 2024. The addition of Mr. Nodelman marks an important step in Galapagos’ ongoing efforts to engage with shareholders and continue to execute on our Forward, Faster strategy to accelerate innovation and create near-and long-term value. [...] “We are pleased to welcome Oleg Nodelman to the Galapagos Board,” said Dr. Paul Stoffels, Galapagos’ CEO and Chair of the Board of Directors1. “His deep expertise in biotech and shared goals of unlocking further value for Galapagos will be instrumental in helping us execute our near- and long-term strategy and deliver superior results for patients, shareholders, employees, and customers.”

• The 2015 Hedge Fund Rising Stars: Oleg Nodelman | Institutional Investor

  Born in Ukraine to an immunologist and an engineer, Oleg Nodelman, 38, took the family flair for science down an unconventional path when he founded biotechnology-focused hedge fund firm EcoR1 Capital in 2013. Nodelman’s family left Kiev for San Diego when he was three years old. In 1996, while a student at Georgetown University, he met his future wife, Heather, at the Summer Olympic Games in Atlanta, where he translated Russian for the broadcasters while she translated Japanese. In 1999, armed with a BS in foreign service, Nodelman moved to San Francisco for a job in strategic consulting and organizational management at Mercer Management Consulting. Two years later he joined BVF Partners, a San Francisco–based hedge fund firm that specializes in biotechnology. There Nodelman learned the [...] specializes in biotechnology. There Nodelman learned the ins and outs of the business as he worked his way up from research analyst to portfolio manager over the next 11 years before leaving to start EcoR1. He named the start-up after an enzyme discovered in the early 1970s that led to DNA cloning — a big step for the young biotech sector — to symbolize his commitment to building the most relevant fund in the industry. The difference between EcoR1 and many other biotech-centric investment managers is that the firm doesn’t bet on the science underlying its prospective investments, which Nodelman argues is more uncertain than people think. The Bay Area–based value investor picks companies with a margin of safety that may stem from intellectual property, unreleased products or partnerships [...] []( Tyler Davies The 2015 Hedge Fund Rising Stars: Oleg Nodelman Nodelman’s EcoR1 Capital stands apart from other biotech-focused investment managers by looking for companies with a margin of safety. Tyler Davies June 15, 2015 2015-06-hedge-fund-rising-stars-oleg-nodelman-small.jpg Oleg Nodelman Oleg Nodelman

• Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth - Lakefront Biotherapeutics

  Mr. Nodelman is the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech-focused investment advisory firm which invests in companies at all stages of research and development. Mr. Nodelman brings a wealth of experience in driving shareholder value, strategic transformations, and long-term growth initiatives. With a proven record in investment management – including business development and capital deployment – and his deep roots in the biotech and scientific communities, Mr. Nodelman’s appointment signals Galapagos’ commitment to accelerating value for all shareholders. [...] Lakefront Biotherapeutics - Lakefront Biotherapeutics - # Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Directors, effective October 7, 2024. Mr. Nodelman replaces Mr. Dan G. Baker who stepped down on October 6, 2024. The addition of Mr. Nodelman marks an important step in Galapagos’ ongoing efforts to engage with shareholders and continue to execute on our Forward, Faster strategy to accelerate innovation and create near-and long-term value. [...] “We are pleased to welcome Oleg Nodelman to the Galapagos Board,” said Dr. Paul Stoffels, Galapagos’ CEO and Chair of the Board of Directors1. “His deep expertise in biotech and shared goals of unlocking further value for Galapagos will be instrumental in helping us execute our near- and long-term strategy and deliver superior results for patients, shareholders, employees, and customers.”